Differential targeting of protein kinase B in cell death induced by sulindac and its metabolite sulindac sulfide

International Journal of Oncology

Volumn 28, Issue 6, 2006, Pages 1471-1479

  Marotta, Anthony ^a   Parhar, Kuljit ^a   Hundal, Rajinder ^a   Duronio, Vincent ^a   Salh, Baljinder ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apoptosis; Caspase activation; Non steroidal anti inflammatory drugs; Protein kinase B

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROTEIN KINASE B; SULINDAC; SULINDAC SULFIDE;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; CELL DEATH; COLON TUMOR; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; KINETICS; METABOLISM; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; COLONIC NEOPLASMS; FLOW CYTOMETRY; HUMANS; KINETICS; PROTO-ONCOGENE PROTEINS C-AKT; SULINDAC;

EID: 33747125836     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.6.1471     Document Type: Article

References (54)

1. Haanen C and Vermes I: Apoptosis: programmed cell death in fetal development. Eur J Obstet Gynecol Reprod Biol 64: 129-133, 1996.
2. Brill A, Torchinsky A, Carp H and Toder V: The role of apoptosis in normal and abnormal embryonic development. J Assist Reprod Genet 16: 512-519, 1999.
3. Grossmann J: Molecular mechanisms of 'detachment-induced apoptosis-Anoikis'. Apoptosis 7: 247-260, 2002.
4. Mullauer L, Gruber P, Sebinger D, Buch J, Wohlfart S and Chott A: Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 488: 211-231, 2001. (Pubitemid 32521033)
5. Warner HR: Apoptosis: a two-edged sword in aging. Anticancer Res 19B: 2837-2842, 1999.
6. Zimmermann J, Lamerant N, Grossenbacher R and Furst P: Proteasome- and p38-dependent regulation of ERK3 expression. J Biol Chem 276: 10759-10766, 2001.
7. Schmitz I, Kirchhoff S and Krammer PH: Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 32: 1123-1136, 2000.
8. Zimmermann KC and Green DR: How cells die: apoptosis pathways. J Allergy Clin Immunol 108 (Suppl. 4): S99-S103, 2001.
9. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
10. Cai J, Yang J and Jones DP: Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta 1366: 139-149, 1998.
11. Browne SJ, MacFarlane M, Cohen GM and Paraskeva C: The adenomatous polyposis coli protein and retinoblastoma protein are cleaved early in apoptosis and are potential substrates for caspases. Cell Death Differ 5: 206-213, 1998. (Pubitemid 28356558)
12. Bachelder RE, Ribick MJ, Marchetti A, Falcioni R, Soddu S, Davis KR and Mercurio AM: p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol 147: 1063-1072, 1999.
13. Steinhusen U, Badock V, Bauer A, Behrens J, Wittman-Liebold B, Dorken B and Bommert K: Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem 275: 16345-16353, 2000.
14. Piazza GA, Alberts DS, Hixson LJ, et al: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57: 2909-2915, 1997.
15. Waddell WR and Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24: 83-87, 1983.
16. Labayle D, Fischer D, Vielh P, et al: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639, 1991.
17. Boolbol SK, Dannenberg AJ, Chadburn A, et al: Cyclooxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56: 2556-2560, 1996.
18. Zhang L, Yu J, Park BH, Kinzler KW and Vogelstein B: Role of BAX in the apoptotic response to anticancer agents. Science 290: 989-992, 2000.
19. Yamamoto Y, Yin MJ, Lin KM and Gaynor RB: Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274: 27307-27314, 1999.
20. Marotta A, Tan C, Gray V, Malik S, Gallinger S, Sanghera J, Dupuis B, Owen D, Dedhar S and Salh B: Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene 20: 6250-6257, 2001.
21. Deguchi A, Thompson WJ and Weinstein IB: Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res 64: 3966-3973, 2004. (Pubitemid 38697311)
22. Hannigan G, Troussard AA and Dedhar S: Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5: 51-63, 2005.
23. Vanhaesebroeck B and Alessi DR: The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346: 561-576, 2000.
24. Tang ED, Nunez G, Barr FG and Guan KL: Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741-16746, 1999.
25. Del Peso L, Gonzalez VM, Hernandez R, Barr FG and Nunez G: Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 18: 7328-7333, 1999. (Pubitemid 30032113)
26. Brunet A, Bonni A, Zigmond MJ, et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
27. Kohn AD, Barthel A, Kovacina KS, et al: Construction and character-ization of a conditionally active version of the serine/threonine kinase Akt. J Biol Chem 273: 11937-11943, 1998.
28. Vanhaesebroeck B and Waterfield MD: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239-254, 1999.
29. Milner AE, Palmer DH, Hodgkin EA, Eliopoulos AG, Knox PG, Poole CJ, Kerr DJ and Young LS: Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Cell Death Differ 9: 287-300, 2002.
30. Wu XX, Kakehi Y, Mizutani Y, Lu J, Terachi T and Ogawa O: Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 19: 19-24, 2001.
31. Ferreira CG, Span SW, Peters GJ, Kruyt FA and Giaccone G: Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 60: 7133-7141, 2000.
32. Huang Y, He Q, Hillman MJ, Rong R and Sheikh MS: Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 61: 6918-6924, 2001.
33. Tang X, Sun YJ, Half E, Kuo MT and Sinicrope F: Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62: 4903-4908, 2002.
34. Huisman C, Ferreira CG, Broker LE, Rodriguez JA, Smit EF, Postmus PE, Kruyt FA and Giaccone G: Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 8: 596-606, 2002.
35. Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S and Shafit-Zagardo B: Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 79: 426-436, 2001.
36. Bidere N and Senik A: Caspase-independent apoptotic pathways in T lymphocytes: a minireview. Apoptosis 6: 371-375, 2001.
37. Belmokhtar CA, Hillion J and Segal-Bendirdjian E: Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene 20: 3354-3362, 2001.
38. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB and Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15: 1406-1418, 2001.
39. Hundal RS, Gomez-Munoz A, Kong JY, Salh BS, Marotta A, Duronio V and Steinbrecher UP: Oxidized low density lipoprotein inhibits macrophage apoptosis by blocking ceramide generation, thereby maintaining protein kinase B activation and Bcl-XL levels. J Biol Chem 278: 24399-24408, 2003.
40. Rokudai S, Fujita N, Hashimoto Y and Tsuruo T: Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis. J Cell Physiol 182: 290-296, 2000.
41. DuBois RN and Smalley WE: Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol 31: 898-906, 1996.
42. Smith WL, De Witt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
43. Smalley WE and DuBois RN: Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39: 1-20, 1997.
44. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Taketo MM: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809, 1996.
45. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB and Whelan J: Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 62: 403-408, 2002.
46. Li M, Wu X and Xu XC: Induction of apoptosis by cyclooxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. Int J Cancer 93: 218-223, 2001. (Pubitemid 32574278)
47. Li M, Wu X and Xu XC: Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7: 1010-1016, 2001. (Pubitemid 32708740)
48. He TC, Chan TA, Vogelstein B and Kinzler KW: PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345, 1999.
49. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998.
50. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403, 2000.
51. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P and Ogier-Denis E: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide- dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277: 27613-27621, 2002.
52. Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001.
53. Graff JR, Konicek BW, McNulty AM, et al: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275: 24500-24505, 2000.
54. Salh B, Marotta A, Wagey R, Sayed M and Pelech S: Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int J Cancer 98: 148-154, 2002.